Article Text

other Versions

PDF
Secukinumab failure in Crohn's disease: the yeast connection?
  1. Jean Frédéric Colombel1,2,
  2. Boualem Sendid2,3,
  3. Thierry Jouault2,
  4. Daniel Poulain2,3
  1. 1Clinique des Maladies de l'Appareil Digestif, Hôpital Huriez, CHRU de Lille, Lille, France
  2. 2Inserm U995, Université Lille Nord de France, Lille, France
  3. 3Laboratoire de Parasitologie- Mycologie, Centre de Biologie Pathologie, CHRU de Lille, Lille, France
  1. Correspondence to Professor Jean Frédéric Colombel, Clinique des Maladies de l'Appareil Digestif, Hôpital Huriez, CHRU, 2 Avenue Oscar Lambret, Lille Cedex 59037, France; Jean-Frederic.COLOMBEL{at}CHRU-LILLE.FR

Statistics from Altmetric.com

We read with great interest the article by Hueber et al1 reporting on the dramatic failure of secukinumab, an anti-IL17A monoclonal antibody, in Crohn's disease (CD). This multicentre phase IIa study compared secukinumab with placebo in 59 patients with established moderate to severe CD. The study was prematurely stopped because the prespecified criterion for futility was met; for the first time to our knowledge in the history of recent CD trials, a statistical significant difference of mean Crohn's Disease Activity Index (CDAI) (between weeks 4 and 10) was observed in favour of placebo. Of the seven serious adverse events suspected to be drug related, five were worsening of CD, four on secukinumab. The study, thus, clearly showed that pharmacological blockade of IL-17A does not improve CD, but that it could …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.